New US fill finish facility receives $4.1 billion investment
European Pharmaceutical Review
JUNE 26, 2024
[the new facility will double] the combined square footage of all three of [Novo Nordisk]’s existing facilities in North Carolina” Overall, the expansion will support Novo Nordisk’s ability to produce injectable treatments for obesity and other chronic diseases such as diabetes. This is compared to the company’s $3.9 (DKK
Let's personalize your content